Emerging opportunities in China’s healthcare sector

The potential of China’s healthcare sector has long intrigued investors. The size of the country’s rapidly aging population, coupled with the still-low level of healthcare spending, suggests that opportunities abound. However, the recent move by the Chinese government to slash generic drug prices is a reminder that experience and expertise are required when navigating the changing landscape and identifying the genuine opportunities that exist.

The long-term outlook for China’s healthcare sector is underpinned by its ageing population and burgeoning healthcare spending.

By 2035, China’s senior citizen population (age over 60) is expected to reach 409 million, representing 28.5% of the total population (see Fig. 1). China’s younger population is, however, smaller due to the lingering impact of the country’s one-child policy. Younger people will carry a higher financial burden to cover the healthcare costs of their ageing relatives in the future.

Fig. 1. Population history and projections for China1

China-Healthcare_Fig 1

Healthcare spending, however, represented just 5.0% of China’s gross domestic product (GDP) in 2016, significantly less than the US which spent 17.1%2. As China’s consumer patterns converge with the developed markets, its healthcare spending could reach RMB 18.04 trillion (USD 2.53 trillion) by 20353.

This translates into a robust annualised growth rate of 8.4% (see Fig. 2), outpacing the country’s economic growth which is hovering at 6.0%.

Fig. 2: China’s healthcare spending projections3

China-Healthcare_Fig 2

At the same time, as China’s life expectancy and affluence levels increase, chronic diseases – such as diabetes – will eventually outweigh acute infectious diseases.

This makes the demand for drugs and medical services more inelastic, and less likely to be affected by external shocks such as the US-China trade dispute.

Thanks for subscribing!

Follow us :

Meanwhile, China’s healthcare stocks – dominated by drug makers (see Fig. 3) – only represent about 7.0% of China’s A-shares market.

Fig. 3: Healthcare’s sub-sectors in China A-shares4

China-Healthcare_Fig 3

This under-representation of China’s vast healthcare market, which only began privatising in the 1990s, suggests that there will be significant opportunities for investors as the market matures.

That said, changing regulations suggest that investors will need to tread carefully to identify potential winners and losers as industry dynamics shift.

A cloudy outlook for pharmaceuticals

Thanks to regulatory preferences, China’s top generic drug makers have enjoyed outsized profit margins of about 18.0%, almost double the global average of 9.5%5 .

This privileged position, however, is set to disappear following the launch of a bulk-purchase drug programme.

In an attempt to slash generic drug prices and free up funding for new drug reimbursements, the National Healthcare Security Administration (NHSA) embarked on the National Centralised Drug Procurement programme in December 2018.

Under this arrangement, more than 11 major cities (one-third of the national market), including Beijing, Guangzhou, Shanghai and Shenzhen6, will combine their purchases of 31 generic drugs (drugs whose patents have expired) and force drug makers to bid for contracts.

So far, this programme has succeeded in cutting drug prices by 52% on average (see Fig. 4).

Fig. 4: Scope and price cuts of 31 generic drugs under the pilot central bulk-purchase programme in 11 Chinese cities7

China-Healthcare_Fig 4

As a result of the programme, the sales of novel medicines and “me-too” drugs – drugs produced by modifying existing ones for more effective therapies – are likely to account for an increasing share of drug sales in China going forward (see Fig. 5).

Fig. 5: Upcoming structural changes in China’s drug markets8

China-Healthcare_Fig 5

In fact, the sales of new drugs on the National Reimbursement Drug List (NDRL) – a list of preferred medicines covered by the government’s health insurance programme – grew 38% in 2018, higher than the general industry sales growth rate of 15%9.

To adapt to this shifting landscape, pharmaceutical companies must optimise their product structure, lower production costs, increase investment in research, and develop more new drugs to compensate for the fall in revenue from generics.

During this transition phase, smaller pharmaceuticals will likely undergo consolidation.

Emerging opportunities in other healthcare sub-sectors

Pharmaceutical companies, are however, not the only way to benefit from China’s growing healthcare needs.

In late 2015, China Food and Drug Administration (CFDA) undertook reforms to speed up innovative drug approvals. The reforms have since paid off and are now under the ambit of the National Medical Products Administration (NMPA).

In 2017, 40 new NDRL drugs were approved, followed by another 51 approvals in 201810. This is a bigger number than the total approved by the agency over the last decade.

With more ‘reimbursement quotas’ released from the bulk-procurement programme and fasttrack approvals on the horizon, we expect to see stronger motivation towards discovering new and patented drugs. This is especially true for those drugs with clinical benefits, and therefore, more likely to get approval.

Contract research organisations (CROs), as in the service “sub-sector” in Fig. 3, are, therefore, well-placed to benefit from this trend (see Fig. 6). These companies provide outsourcing research support to pharmaceutical companies and the medical device industry.

Fig. 6: Market size and growth outlook for healthcare sub-sectors11

China-Healthcare_Fig 6

CROs that specialise in clinical trials can even offer drug sponsors the expertise required for taking a new drug or device from its conception until the NMPA’s approval, without the drug sponsor having to maintain permanent staff for such services.

Other healthcare players also present attractive opportunities. These include:

  • Specialist medical services: Chinese consumers are demanding more personalised and higher quality healthcare services. This has led to robust growth in private health check-ups, as well as other specialist medical services such as ophthalmology and dental care.
  • Medical equipment providers: Closely tied with domestic demand, these are potential beneficiaries of the US-China trade tensions, since they provide alternatives for imported equipment.

Seizing the opportunities; navigating the challenges

China’s healthcare stocks sold off significantly in December 2018 over concerns of earnings downgrades following the bulk-procurement programme for generic drugs.

The S&P/CITIC Health Care index, for example, fell 10.6% in December 2018, and recovered 18.5% in the first six months of 2019, during which the CSI 300 index recorded a stronger return of 28.3%12.

Whilst the healthcare sector has historically traded at a premium to the broader market, the recent underperformance has reduced the 52- week rolling price-earnings (P/E) premium to a low of 10.6x (see Fig.7).

Fig. 7: Valuation premiums of China’s healthcare A-shares13

China-Healthcare_Fig 7

Not all healthcare stocks are the same, however. Investors looking to take advantage of the relatively cheap valuations need to be aware of the potential corporate governance risks.

China’s healthcare market remains complicated and fragmented. Some local Chinese healthcare companies may have inscrutable and opaque financials; investors therefore will need to be able to detect and assess the associated business risks.

This is not the only caveat. Whilst healthcare is normally regarded as a defensive sector across economic cycles in developed markets, policy uncertainty and government’s healthcare cost control, such as the bulk-procurement programme, may trigger risk appetite changes. That said, this may also create huge growth opportunities for certain sub sectors.

All in all, asset managers who can understand the implications of China’s changing regulatory trends and identify emerging leaders are well positioned to fully tap into the potential of China’s booming healthcare sector.

At present, we are selective in pharmaceuticals concentrating on generics produced using their own active pharmaceutical ingredients, as they might fare better in resisting price pressure.

With this in mind, we favour pharmaceutical companies with rich, innovative product pipelines. We also see opportunities in selected CROs as well as providers of specialist medical services and medical equipment.

For Use with Professional Clients / Qualified Investors Only. Not Approved for Further Distribution or Use with the General Public.

1 United Nations, Department of Economics and Social Affairs, data obtained on 12 June 2019.
2 https://www.theglobaleconomy.com/USA/ latest available data for 2016.
3 China’s Health Expenditure Projections To 2035: Future Trajectory And The Estimated Impact Of Reforms, May 2019. https://doi.org/10.1377/ hlthaff.2018.05324, by Tiemin Zhai, John Goss, Tania Dmytraczenko, Yuhui Zhang, Jinjing Li, and Peipei Chai. Authors’ analysis of data from the China National Health Accounts Report, Institute for Health Metrics and Evaluation, and China Population and Development Research Center. NOTES Data are in constant 2014 prices.
4 Eastspring Investments, as at 10 June 2019, excluding companies whose main business line has changed or unclear.
5 Bloomberg, 2 Jan 2019. Even After a $46 Billion Plunge, China’s Drugmakers May Have a Long Way to Fall.
6 China Daily: China unveils pilot ‘group-buying’ plan to cut drug prices, updated on 17 Jan 2019.
7 SMPA, PDB database, Guosen Research, and Eastspring Investments.
8 Eastspring Investment, Jun 2019.
9 CDE, PDB database, Eastspring Investments, Dec 2017.
10 Deloitte LLP, citing CDE published the priority review of drug inventory, batch 26 to 33, Centre for Drug Evaluation, NMPA, 29 January 2018-17 October 2018.
11 Eastspring Investments, Dec 2018. CAGR refers to compound annual growth rate.
12 Bloomberg, S&P/CITIC Composite Health Care Sector Total Return Index (202 A-shares), from 30 Nov to 31 Dec 2018, and from 31 Dec 2018 to 28 Jun 2019, total returns in Chinese renminbi. S&P/CITIC Composite Health Care Index is a market capitalization weighted index represents the entire A-Shares stocks listed on the Shanghai and Shenzhen Stock Exchanges that represents the health care sector using the Global Industry Classification Standard (GICS®). The CSI 300 Index is a free-float weighted index that consists of 300 A-share stocks listed on the Shanghai or Shenzhen Stock Exchanges.
13 Bloomberg, Best P/Es for S&P/CITIC Composite Health Care Sector, CSI 300 Index, weekly data, as at 28 Jun 2019, in Chinese renminbi. S&P/CITIC Composite Health Care Index is a market capitalization weighted index represents the entire A-Shares stocks listed on the Shanghai and Shenzhen Stock Exchanges that represents the health care sector using the Global Industry Classification Standard (GICS®). The CSI 300 Index is a free-float weighted index that consists of 300 A-share stocks listed on the Shanghai or Shenzhen Stock Exchanges.

The information and views expressed herein do not constitute an offer or solicitation to deal in shares of any securities or financial instruments and it is not intended for distribution or use by anyone or entity located in any jurisdiction where such distribution would be unlawful or prohibited. The information does not constitute investment advice or an offer to provide investment advisory or investment management service or the solicitation of an offer to provide investment advisory or investment management services in any jurisdiction in which an offer or solicitation would be unlawful under the securities laws of that jurisdiction.

Past performance and the predictions, projections, or forecasts on the economy, securities markets or the economic trends of the markets are not necessarily indicative of the future or likely performance of Eastspring Investments or any of the strategies managed by Eastspring Investments. An investment is subject to investment risks, including the possible loss of the principal amount invested. Where an investment is denominated in another currency, exchange rates may have an adverse effect on the value price or income of that investment. Furthermore, exposure to a single country market, specific portfolio composition or management techniques may potentially increase volatility.

Any securities mentioned are included for illustration purposes only. It should not be considered a recommendation to purchase or sell such securities. There is no assurance that any security discussed herein will remain in the portfolio at the time you receive this document or that security sold has not been repurchased.

The information provided herein is believed to be reliable at time of publication and based on matters as they exist as of the date of preparation of this report and not as of any future date. Eastspring Investments undertakes no (and disclaims any) obligation to update, modify or amend this document or to otherwise notify you in the event that any matter stated in the materials, or any opinion, projection, forecast or estimate set forth in the document, changes or subsequently becomes inaccurate. Eastspring Investments personnel may develop views and opinions that are not stated in the materials or that are contrary to the views and opinions stated in the materials at any time and from time to time as the result of a negative factor that comes to its attention in respect to an investment or for any other reason or for no reason. Eastspring Investments shall not and shall have no duty to notify you of any such views and opinions. This document is solely for information and does not have any regard to the specific investment objectives, financial or tax situation and the particular needs of any specific person who may receive this document.

Eastspring Investments Inc. (Eastspring US) primary activity is to provide certain marketing, sales servicing, and client support in the US on behalf of Eastspring Investment (Singapore) Limited (“Eastspring Singapore”). Eastspring Singapore is an affiliated investment management entity that is domiciled and registered under, among other regulatory bodies, the Monetary Authority of Singapore (MAS). Eastspring Singapore and Eastspring US are both registered with the US Securities and Exchange Commission as a registered investment adviser. Registration as an adviser does not imply a level of skill or training. Eastspring US seeks to identify and introduce to Eastspring Singapore potential institutional client prospects. Such prospects, once introduced, would contract directly with Eastspring Singapore for any investment management or advisory services. Additional information about Eastspring Singapore and Eastspring US is also is available on the SEC’s website at www.adviserinfo.sec. gov.

Certain information contained herein constitutes "forward-looking statements", which can be identified by the use of forward-looking terminology such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue" or "believe" or the negatives thereof, other variations thereof or comparable terminology. Such information is based on expectations, estimates and projections (and assumptions underlying such information) and cannot be relied upon as a guarantee of future performance. Due to various risks and uncertainties, actual events or results, or the actual performance of any fund may differ materially from those reflected or contemplated in such forward-looking statements.

Eastspring Investments companies (excluding JV companies) are ultimately wholly-owned / indirect subsidiaries / associate of Prudential plc of the United Kingdom. Eastspring Investments companies (including JV’s) and Prudential plc are not affiliated in any manner with Prudential Financial, Inc., a company whose principal place of business is in the United States of America.